Conscience publishes first Annual Report
Conscience has published its latest Annual Report, highlighting a year of progress in advancing open science drug discovery and building the foundations for long-term impact across the research and innovation ecosystem. In 2025, Conscience moved from concept to execution, funding the first projects through the Developing Medicines through Open Science (DMOS) program, expanding the CACHE […]
New program to fund AI and digital tools for drug discovery and development
We’re pleased to announce the launch of our new AI-driven Medicines (AIM) program. This program aims to drive transformative research that leverages computational or digital-based methods and tools to address critical, real-world challenges in the discovery and development of accessible and affordable medicines. This initiative focuses on supporting the development of innovative methodologies and tools […]
BEACON and Conscience featured in STAT News
For decades, they’ve set the record straight in biology. Next up: science’s reproducibility crisis By Brittany Trang This STAT News feature explores the launch of BEACON (the Benchmarking, Evaluation, and Assessment Consortium for Science), a new international effort to strengthen how scientific research is evaluated, benchmarked, and translated into reliable knowledge. Coordinated by Conscience, BEACON […]
What Rare Disease Research Teaches Us About the Future of Precision Medicine
In honor of Rare Disease Day, our VP of Drug Discovery, Anne Fortier, published an insightful piece in The Scientist. The piece highlights how strategies perfected by the rare disease research community could provide the blueprint for the future of precision medicine for all. As our understanding of molecular biology deepens, the concept of the […]
Introducing BEACON: The Benchmarking, Evaluation, and Assessment Consortium for Science
We’re pleased to announce the launch of BEACON, a new open benchmarking consortium established through a collaborative effort by its founding partners from five organizations with deep expertise and proven track records in benchmarking and critical assessment: CASP, DREAM, OpenADMET, Sage Bionetworks, and CACHE/Conscience. The consortium aims to increase the collective impact of critical assessment […]
DMOS-funded project featured in Canadian SME Magazine
This piece in CanadianSME Small Business Magazine features Peter Sampson of the Agora Open Science Trust, who leads a project using open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. The project recently reached an important milestone for open science drug […]
Beyond the Competition: Insights from Returning CACHE Participants
Open science competitions, such as Conscience’s CACHE Challenges, provide multiple benefits for early-stage drug discovery and the companies and researchers that participate in them. While hit-finding is the ultimate goal, the impact of participating in a challenge goes far beyond the competition itself. The challenges offer an opportunity to share data across organizations, accelerate discovery, […]
Second call for applications for expanded DMOS program includes clinical research
We’re pleased to announce that applications are now open for the second round of our Developing Medicines through Open Science (DMOS) program and that the program has expanded to support clinical-stage projects alongside preclinical research. This expansion reflects our commitment to moving promising therapies closer to patients while continuing to apply open science principles that […]
Open Science as a Catalyst for Canada’s Innovation Strategy
Innovation depends on the ability to share and build on ideas, yet too much scientific knowledge remains siloed. In this op-ed for the Canadian Science Policy Centre, Conscience’s Richard Gold and Estrid Jakobsen argue that open science should be a central pillar of Canada’s innovation strategy, particularly in an era shaped by AI, health challenges, […]
Agora Open Science Trust selects lead development candidate for pediatric brain cancer therapy
We’re pleased to share a joint press release with the Agora Open Science Trust announcing the nomination of M4K2009 as the lead development candidate in their open science program for DIPG, a rare and devastating pediatric brain cancer. This milestone reflects the strength of collaborative, open science-driven research and highlights the meaningful progress supported through […]
Conscience and Every Cure launch partnership to advance drug repurposing
We are pleased to announce a new partnership with Every Cure. Every Cure is a U.S.-based nonprofit on a mission to save and improve lives by repurposing drugs; the organization leverages AI to uncover new uses for existing medicines to address diseases with high unmet need. They validate the most promising opportunities through laboratory research […]
Intellectual Property Strategies in the age of AI
In this recently published op-ed in CanadianSME, Conscience’s Chief Policy and Partnerships Officer, Richard Gold, and CEO, Peng Fu, call for biopharma SMEs to rethink their reliance on patents as they adopt AI. They argue that traditional patent-first IP strategies are increasingly misaligned with how AI actually works, because machine learning depends on broad data […]
